GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » EV-to-Revenue

PDS Biotechnology (PDS Biotechnology) EV-to-Revenue : (As of Apr. 27, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PDS Biotechnology's enterprise value is $86.87 Mil. PDS Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, PDS Biotechnology's EV-to-Revenue for today is .

The historical rank and industry rank for PDS Biotechnology's EV-to-Revenue or its related term are showing as below:

PDSB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.66
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-27), PDS Biotechnology's stock price is $3.27. PDS Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, PDS Biotechnology's PS Ratio for today is .


PDS Biotechnology EV-to-Revenue Historical Data

The historical data trend for PDS Biotechnology's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology EV-to-Revenue Chart

PDS Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PDS Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PDS Biotechnology's EV-to-Revenue

For the Biotechnology subindustry, PDS Biotechnology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's EV-to-Revenue falls into.



PDS Biotechnology EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PDS Biotechnology's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=86.866/0
=

PDS Biotechnology's current Enterprise Value is $86.87 Mil.
PDS Biotechnology's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology  (NAS:PDSB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PDS Biotechnology's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=3.27/0
=

PDS Biotechnology's share price for today is $3.27.
PDS Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PDS Biotechnology EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PDS Biotechnology (PDS Biotechnology) Business Description

Traded in Other Exchanges
Address
25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932
PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Executives
Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus